The power of creativity Pharmaceutical Branding 2012

Size: px
Start display at page:

Download "The power of creativity www.originbranding.com. Pharmaceutical Branding 2012"

Transcription

1 The power of creativity Pharmaceutical Branding 2012

2 We are an independent, boutique agency passionately focused on developing pharmaceutical brands. For over 15 years we have delivered outstanding branding solutions for our clients from our offices in Surrey, UK and Birmingham, Michigan. Developing a brand identity that communicates your brand message, ensures differentiation and clears the relevant trademark screening and regulatory checks can be a challenging task. Our proven branding process has been built on creativity, flexibility and a strong understanding of all the issues and challenges surrounding the registration of a new identity, irrespective of geographical or business area. Many examples of our naming, design and research projects are presented in the following pages and additional examples of our work in the pharmaceutical and other industries can be found in our website. We look forward to speaking with you about your branding challenges! Abbott Products Allergan Alliance Pharma Astellas AstraZeneca Axis-Shield Baxter Bayer BD Biotest DuoCort DuPont Ferring Fresenius Galderma Grünenthal GlaxoSmithKline Intercytex Intervet Janssen Pharmaceutica Johnson & Johnson Lundbeck Merck Merck Serono Novartis Novo Nordisk Nycomed Orion Pharma Procter & Gamble Pfizer Philips Medical Roche Shire Sanofi UCB

3 Janssen Pharmaceutica - Xeplion Janssen Pharmaceutica s once monthly, long-acting injectable, antipsychotic for the treatment of schizophrenia. Xeplion is a dynamic, impactful, strong and modern sounding name reflecting the innovative approach to the treatment. DuoCort - Plenadren DuoCort s new treatment for Addison s disease, a rare and life threatening adrenal insufficiency disease. Instantly meaningful and easily communicated, Plenadren is derived from plenty and adrenal and conveys confidence, re-assurance and increased control. Abbott Products Allergan Alliance Pharma Astellas AstraZeneca Axis-Shield Baxter Bayer BD Biotest DuoCort DuPont Ferring Fresenius Galderma Grünenthal GlaxoSmithKline Intercytex Intervet Janssen Pharmaceutica Johnson & Johnson Lundbeck Merck Merck Serono Novartis Novo Nordisk Nycomed Orion Pharma Procter & Gamble Pfizer Philips Medical Roche Shire Sanofi UCB

4 Bayer - Levitra ODT Origin created the Levitra brand name for Bayer and were later asked to create an innovative, added-value packaging for the new ODT formulation. We created a unique system that included a pull out tab containing key information for the patient. The blister pack is encased in a discreet matt black sleeve to create a luxurious and empowering user experience. Bayer and Johnson & Johnson - Xarelto Bayer and Johnson & Johnson s oral anti-coagulant to prevent blood clots after orthopaedic surgery. Xarelto is a ground breaking new factor Xa inhibitor. The name is modern, impactful and resonates with prescribers and patients alike, characteristics that re-enforce the key brand message. Abbott Products Allergan Alliance Pharma Astellas AstraZeneca Axis-Shield Baxter Bayer BD Biotest DuoCort DuPont Ferring Fresenius Galderma Grünenthal GlaxoSmithKline Intercytex Intervet Janssen Pharmaceutica Johnson & Johnson Lundbeck Merck Merck Serono Novartis Novo Nordisk Nycomed Orion Pharma Procter & Gamble Pfizer Philips Medical Roche Shire Sanofi UCB

5 Firmagon Packaging development for a hormonal therapy for prostate cancer Omnic Wowtab Visual identity for an orodispersible urology formulation for Astellas Replagal An enzyme replacement therapy for patients with Fabry disease Elaprase Indicated for patients with Hunter syndrome Posidorm A new brand of melatonin that promotes better sleep in a variety of sleep disorders Flomaxtra Brand Identity for a BPH (Benign Prostatic Hyperplasia) treatment

6 Shire - Elaprase Elaprase is indicated for patients with Hunter syndrome. A global set of packaging including over 500 pieces of artwork was created for use across all countries applying the latest regulatory information. Abbott Products Allergan Alliance Pharma Astellas AstraZeneca Abbott (Solvay) - Creon Axis-Shield Baxter Origin consolidated a variety of differing brand logos to Bayer create a single global presence. This new identity capitalises BD Biotest on Solvay s expertise and Creon s patented minimicrosphere DuoCort technology which allows appropriate delivery of enzymes DuPont into the body. Ferring Fresenius Galderma Grünenthal GlaxoSmithKline Intercytex Intervet Janssen Pharmaceutica Johnson & Johnson Lundbeck Merck Merck Serono Novartis Novo Nordisk Nycomed Orion Pharma Procter & Gamble Pfizer Philips Medical Roche Shire Sanofi UCB

7 NovoPen Echo Insulin pen from Novo Nordisk designed for children with diabetes ACCU-CHEK Inform Roche Diagnostics fully integrated portable blood glucose testing system Isprelor A name and logo of misoprostol for Alliance Pharmaceuticals Nexiva BD Nexiva Closed IV Catheter System Omnifuse Infusion syringe pump system for Smiths Industries Afinion A point of care multiparameter analyser system for Axis-Shield

8 Afinitor Novartis treatment for renal cell carcinoma Caprelsa AstraZeneca s kinase inhibitor indicated for thyroid cancer Selincro Lundbeck s treatment for alcohol dependency Levitra Erectile dysfunction drug, co-marketed by Bayer and GSK Prezista HIV protease inhibitor from Tibotec Zutectra Biotest s drug for the prevention of hepatitis B after liver transplantation

9 Brand naming Brand name generation Tagline/brand statement development Brand naming architecture INN name generation Brand design Symbol/logotype development Packaging design Identity guidelines Pharmaceutical artwork Brand strategy Strategic brand analysis Portfolio analysis Brand extension/ positioning Visual brand evaluation Brand market research Brand equity/awareness studies Name validation Linguistic screening Trademark/legal pre-screening Safety testing Scriptability testing UK Office: Bridge House, 72 Bridge Road, East Molesey, Surrey KT8 9HF Tel: +44(0) US Office: 200 Elm Street, Birmingham, MI Tel:

Outcomes of Monitoring Committee Reviews. Medicines Australia Code of Conduct

Outcomes of Monitoring Committee Reviews. Medicines Australia Code of Conduct Outcomes of Monitoring Committee Reviews Medicines Australia Code of Conduct 1 Medicines Australia ABN 23 126 990 001 Level 1, 16 Napier Close Deakin ACT 2600 Phone: 02 6122 8500 Fax: 02 6122 8555 Web:

More information

CHEM-E4140 Selectivity 12. Pharma Business

CHEM-E4140 Selectivity 12. Pharma Business CHEM-E4140 Selectivity 12. Pharma Business Prof. Ari Koskinen Laboratory of Organic Chemistry C318 Pharma Business Total volume ca 1100 G$ (Shell 421G$; Walmart 486G$; Toyota 252 G$). Annually approx 25

More information

Decision Matrix: Selecting a CRM Vendor in the Pharmaceutical Market (Competitor Focus)

Decision Matrix: Selecting a CRM Vendor in the Pharmaceutical Market (Competitor Focus) A Datamonitor report Decision Matrix: Selecting a CRM Vendor in the Pharmaceutical Market (Competitor Focus) Published: Oct 07 Product Code: DMTC2133 Providing you with: Identifies which technology vendors

More information

Stakeholder Insight: Insulin Use in Type 2 Diabetes

Stakeholder Insight: Insulin Use in Type 2 Diabetes A Datamonitor Report Stakeholder Insight: Insulin Use in Type 2 Diabetes From Last Resort to Early Intervention Published: May-04 Product Code: DMHC1989 Providing you with: Analysis of Datamonitor s Diabetes

More information

Pharma working capital performance highly variable

Pharma working capital performance highly variable April 2014 Pharma working capital performance highly variable 41 Billion in Excess Working Capital We last completed this survey in 2012. We expected that there would be a broad improvement across the

More information

Stakeholder Perspectives: Mild Cognitive Impairment and Dementia

Stakeholder Perspectives: Mild Cognitive Impairment and Dementia A Datamonitor In-Depth Analysis Stakeholder Perspectives: Mild Cognitive Impairment and Dementia Aricept in Race to Pioneer Unexplored Markets Published: Aug-03 Product Code: DMHC1924 Why buy this analysis?

More information

KEEPING CLINICAL TRIALS IN AUSTRALIA

KEEPING CLINICAL TRIALS IN AUSTRALIA OCCASIONAL PAPER SERIES KEEPING CLINICAL TRIALS IN AUSTRALIA WHY ACTION IS NEEDED NOW OCCASIONAL PAPER SERIES > Medicines Australia is producing Occasional Papers to promote a contest of ideas, thought

More information

Commercial Insight Osteoarthritis and Rheumatoid Arthritis

Commercial Insight Osteoarthritis and Rheumatoid Arthritis A Datamonitor In-Depth Analysis Commercial Insight Osteoarthritis and Rheumatoid Arthritis New Growth In A Mature Market Published: Jul-03 Product Code: DMHC1891 Why buy this analysis? Target current and

More information

Annual Press Conference 2012. Business Year 2011

Annual Press Conference 2012. Business Year 2011 Business Year 2011 Highlights of the Business Year 2011 Andreas Barner Chairman of the Board of Managing Directors Corporate Board Division Pharma Research, Development and Medicine Value through Innovation

More information

Join our scientific talent community

Join our scientific talent community Join our scientific talent community There has never been a better time to be a part of Janssen Research & Development. We are at the forefront of healthcare leading, evolving and transforming it into

More information

Prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation (AF) with one or more risk factors

Prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation (AF) with one or more risk factors News Release For use outside the US and UK only Bayer Pharma AG 13342 Berlin Germany Tel. +49 30 468-1111 www.bayerpharma.com Bayer s Xarelto Approved in the EU for the Prevention of Stroke in Patients

More information

December 17, 2014 HOW PHARMA MARKETERS FIND AND SELECT DIGITAL MARKETING AGENCIES

December 17, 2014 HOW PHARMA MARKETERS FIND AND SELECT DIGITAL MARKETING AGENCIES December 17, 2014 HOW PHARMA MARKETERS FIND AND SELECT DIGITAL MARKETING AGENCIES by Dennis van Rooij with Tim van Tongeren EXECUTIVE SUMMARY More than half of pharma marketers don t or can t leverage

More information

Key Findings. Use this report to... The Autoimmune Market Outlook to 2013

Key Findings. Use this report to... The Autoimmune Market Outlook to 2013 Key Findings The global autoimmune market generated sales of $31.9bn in, an increase of 14.4% over 2006 sales. The market is forecast to grow at a CAGR of 8.1% to reach a total value of $51.0bn in 2013.

More information

ehealthinsight Series: Online Patient Recruitment Strategies

ehealthinsight Series: Online Patient Recruitment Strategies A Datamonitor report ehealthinsight Series: Online Patient Recruitment Strategies Published: May-08 Product Code: Providing you with: Overview of benefits and drawbacks of online Analysis of online patient

More information

Chapter 1 INTRODUCTION GLOBAL MARKETS FOR EMERGING INSULIN DRUG AND DELIVERY TECHNOLOGIES HLC149A. Shalini Shahani Dewan Project Analyst

Chapter 1 INTRODUCTION GLOBAL MARKETS FOR EMERGING INSULIN DRUG AND DELIVERY TECHNOLOGIES HLC149A. Shalini Shahani Dewan Project Analyst Chapter 1 INTRODUCTION GLOBAL MARKETS FOR EMERGING INSULIN DRUG AND DELIVERY TECHNOLOGIES HLC149A Shalini Shahani Dewan Project Analyst ISBN: 1-56965-521-9 BCC Research 49 Walnut Park, Building 2 Wellesley,

More information

Commercial Perspectives: Multiple Sclerosis

Commercial Perspectives: Multiple Sclerosis A Datamonitor Report Commercial Perspectives: Multiple Sclerosis How to Find Opportunities in an Unremitting Market Published: Jun-04 Product Code: Providing you with: In-depth profiles of current market-leading

More information

New Treatments. For Bipolar Disorder. Po W. Wang, MD Clinical Associate Professor Bipolar Disorders Clinic Stanford University School of Medicine

New Treatments. For Bipolar Disorder. Po W. Wang, MD Clinical Associate Professor Bipolar Disorders Clinic Stanford University School of Medicine New Treatments For Bipolar Disorder Po W. Wang, MD Clinical Associate Professor Bipolar Disorders Clinic Stanford University School of Medicine Abbott Laboratories AstraZeneca Bristol-Myers Squibb Corcept

More information

e-labeling : innovation for patient or regulation nightmare Pharmapack Feb, 11 th, 2015

e-labeling : innovation for patient or regulation nightmare Pharmapack Feb, 11 th, 2015 e-labeling : innovation for patient or regulation nightmare Pharmapack Feb, 11 th, 2015 PHARMAPACK 2015 1 Mobile health x2 30 months 100 000 mapps Source: research2guidance, mhealth App Market Report 2013-2017

More information

Pharmaceutical Marketing Disclosures

Pharmaceutical Marketing Disclosures Pharmaceutical Marketing Disclosures July 1, 2007 June 30, 2008 Report of Vermont Attorney General William H. Sorrell April 2009 Prepared by staff of the Vermont Attorney General s Office: Wendy Morgan,

More information

Pharma RepTrak 2015 The World s Most Reputable Pharmaceutical Companies

Pharma RepTrak 2015 The World s Most Reputable Pharmaceutical Companies Pharma RepTrak 2015 The World s Most Reputable Pharmaceutical Companies The Pharma Industry s Reputation in the Eyes of the General Public A Reputation Study with Consumers in 15 Countries RepTrak is a

More information

The Evolution of Data Platforms in IMI. Anthony Rowe, Janssen R&D IT 08 April 2016 Med-e-Tel Luxembourg

The Evolution of Data Platforms in IMI. Anthony Rowe, Janssen R&D IT 08 April 2016 Med-e-Tel Luxembourg The Evolution of Data Platforms in IMI Anthony Rowe, Janssen R&D IT 08 April 2016 Med-e-Tel Luxembourg Three trends in technology today Ubiquity of the Internet Three trends in technology today Ubiquity

More information

Bayer Pharma AG 13342 Berlin Germany Tel. +49 30 468-1111 www.bayerpharma.com. News Release. Not intended for U.S. and UK Media

Bayer Pharma AG 13342 Berlin Germany Tel. +49 30 468-1111 www.bayerpharma.com. News Release. Not intended for U.S. and UK Media News Release Not intended for U.S. and UK Media Bayer Pharma AG 13342 Berlin Germany Tel. +49 30 468-1111 www.bayerpharma.com Bayer Forms Collaboration with Academic and Governmental Institutions for Rivaroxaban

More information

Abnormal Uterine Bleeding FAQ Sheet

Abnormal Uterine Bleeding FAQ Sheet Abnormal Uterine Bleeding FAQ Sheet What is abnormal uterine bleeding? Under normal circumstances, a woman's uterus sheds a limited amount of blood during each menstrual period. Bleeding that occurs between

More information

US Diabetic Devices Industry Research Report: KenResearch

US Diabetic Devices Industry Research Report: KenResearch US Diabetic Devices Industry Research Report: KenResearch by KenResearch - Monday, February 24, 2014 https://www.kenresearch.com/blog/2014/02/us-diabetic-devices-industry-research-report-kenresearch/ The

More information

Liver Function Essay

Liver Function Essay Liver Function Essay Name: Quindoline Ntui Date: April 20, 2009 Professor: Dr. Danil Hammoudi Class: Anatomy and Physiology 2 Liver function The human body consist of many highly organize part working

More information

EBiSC the first European bank for induced pluripotent stem cells

EBiSC the first European bank for induced pluripotent stem cells Press Release EBiSC the first European bank for induced pluripotent stem cells Pharmaceutical companies who are members of the European Federation of Pharmaceutical Industries and Associations (EFPIA)

More information

GLOBAL MARKETS FOR EMERGING INSULIN DRUG AND DELIVERY TECHNOLOGIES - FOCUS ON INSULIN PENS. HLC157A August 2013. Shalini Shahani Dewan Project Analyst

GLOBAL MARKETS FOR EMERGING INSULIN DRUG AND DELIVERY TECHNOLOGIES - FOCUS ON INSULIN PENS. HLC157A August 2013. Shalini Shahani Dewan Project Analyst GLOBAL MARKETS FOR EMERGING INSULIN DRUG AND DELIVERY TECHNOLOGIES - FOCUS ON INSULIN PENS HLC157A August 2013 Shalini Shahani Dewan Project Analyst ISBN: 1-56965-531-6 BCC Research 49 Walnut Park, Building

More information

THE BIOTECH & PHARMACEUTICAL INDUSTRY

THE BIOTECH & PHARMACEUTICAL INDUSTRY THE BIOTECH & PHARMACEUTICAL INDUSTRY ESSENTIAL CAREERS INFORMATION CALUM LECKIE KATIE BISARO CAREERS CONSULTANTS What we will cover Sector overview Types of role Graduate recruitment trends and issues

More information

Pharma working capital leaves room for improvement

Pharma working capital leaves room for improvement October 2012 Pharma working capital leaves room for improvement 50.7 Billion in Excess Working Capital Ten years ago it was not unusual to be asked why working capital mattered to a pharmaceutical company.

More information

Oracle Buys Phase Forward Expands Oracle s solutions for the life sciences and healthcare industries

Oracle Buys Phase Forward Expands Oracle s solutions for the life sciences and healthcare industries Oracle Buys Phase Forward Expands Oracle s solutions for the life sciences and healthcare industries April 16, 2010 Oracle is currently reviewing the existing Phase Forward product roadmap and will be

More information

Prior Authorization Guideline

Prior Authorization Guideline Prior Authorization Guideline Guideline: PC (CO) - Insulin Delivery Systems Therapeutic Class: Hormones and Synthetic Substitutes Therapeutic Sub-Class: Insulin Delivery Systems Client: CO Approval Date:

More information

Medicare Drug Coverage Under Part A, Part B, and Part D

Medicare Drug Coverage Under Part A, Part B, and Part D Medicare Drug Coverage Under Part A, Part B, and Part D Medicare Part A and Part B generally do not cover outpatient prescription drugs, most of which are now covered under Part D. This document and the

More information

group insurance The Tiered Plan with Dynamic Therapeutic Formulary Why pay more than you have to for your prescription drugs?

group insurance The Tiered Plan with Dynamic Therapeutic Formulary Why pay more than you have to for your prescription drugs? group insurance The Tiered Plan with Dynamic Therapeutic Formulary Why pay more than you have to for your prescription drugs? The constantly increasing cost of prescription drugs makes it a challenge to

More information

SHORT CLINICAL GUIDELINE SCOPE

SHORT CLINICAL GUIDELINE SCOPE NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE SHORT CLINICAL GUIDELINE SCOPE 1 Guideline title Type 2 diabetes: newer agents for blood glucose control in type 2 diabetes 1.1 Short title Type 2

More information

Multiple Sclerosis. Current and Future Players. GDHC1009FPR/ Published March 2013

Multiple Sclerosis. Current and Future Players. GDHC1009FPR/ Published March 2013 Multiple Sclerosis Current and Future Players GDHC1009FPR/ Published March 2013 Executive Summary Moderate Growth in the Multiple Sclerosis Market is Expected from 2012 2022 GlobalData estimates the 2012

More information

EINSTEIN PE Data Summary & Perspectives on XARELTO (rivaroxaban) in ORS & NVAF. Recorded Webcast Update for Analysts and Investors March 26, 2012

EINSTEIN PE Data Summary & Perspectives on XARELTO (rivaroxaban) in ORS & NVAF. Recorded Webcast Update for Analysts and Investors March 26, 2012 EINSTEIN PE Data Summary & Perspectives on XARELTO (rivaroxaban) in ORS & NVAF Recorded Webcast Update for Analysts and Investors March 26, 2012 1 Webcast Presentation Agenda EINSTEIN PE Clinical Trial

More information

Small-Cell Lung Cancer Global Clinical Trials Review, H2, 2015

Small-Cell Lung Cancer Global Clinical Trials Review, H2, 2015 Brochure More information from http://www.researchandmarkets.com/reports/3398017/ Small-Cell Lung Cancer Global Clinical Trials Review, H2, 2015 Description: Small-Cell Lung Cancer Global Clinical Trials

More information

Go for the complete package.

Go for the complete package. Go for the complete package. Our services help you stand out in the market. Individual design options while leveraging the benefits of a device platform Flexible prototyping and devices for early studies

More information

Bayer Extends Clinical Investigation of Xarelto for the Prevention and Treatment of Life-Threatening Blood Clots in Patients with Cancer

Bayer Extends Clinical Investigation of Xarelto for the Prevention and Treatment of Life-Threatening Blood Clots in Patients with Cancer Investor News Not intended for U.S. and UK Media Bayer AG Investor Relations 51368 Leverkusen Germany www.investor.bayer.com Bayer Extends Clinical Investigation of Xarelto for the Prevention and Treatment

More information

novo nordisk Partnering for innovation IN PROTEIN-BASED THERAPEUTICS AND TECHNOLOGIES Protein Technologies Diabetes Protein Delivery Devices

novo nordisk Partnering for innovation IN PROTEIN-BASED THERAPEUTICS AND TECHNOLOGIES Protein Technologies Diabetes Protein Delivery Devices novo nordisk Partnering for innovation IN PROTEIN-BASED THERAPEUTICS AND TECHNOLOGIES Juan Jenny Li works as a chemistry professional at Novo Nordisk s research centre in Beijing Diabetes Protein Technologies

More information

A list of all medications you are taking also include any vitamins, supplements, over-the-counter medicines, or herbal products

A list of all medications you are taking also include any vitamins, supplements, over-the-counter medicines, or herbal products This is your customized insulin discussion guide to bring to your next doctor s visit. WHAT TO BRING TO YOUR NEXT CHECK UP A record of your recent blood sugar readings A list of all medications you are

More information

Avoca s Quality Metrics Consulting Service Offering

Avoca s Quality Metrics Consulting Service Offering Avoca s Quality Metrics Consulting Service Offering Avoca s Quality Metrics Consulting The Challenge Biopharmaceutical companies and CROs struggle in defining how best to utilize quality metrics to optimize

More information

Erectile Dysfunction (ED)

Erectile Dysfunction (ED) Information from your Patient Aligned Care Team What is Erectile Dysfunction or ED? Erectile dysfunction (also known as impotence) is the inability to get and keep an erection firm enough for sex. Having

More information

Q3 2015 Conference Call

Q3 2015 Conference Call November 4, 2015 Q3 2015 Conference Call 1 Safe Harbour This presentation includes forward-looking statements. Actual results could differ materially from those included in the forward-looking statements

More information

TO: HELENA SALES, POC SPECALISTS, INTERNATIONAL DISTRIBUTORS FROM: HELENA HEMOSTASIS/POINT OF CARE SUBJECT: ROUND-UP DATE: 11/10/2010

TO: HELENA SALES, POC SPECALISTS, INTERNATIONAL DISTRIBUTORS FROM: HELENA HEMOSTASIS/POINT OF CARE SUBJECT: ROUND-UP DATE: 11/10/2010 TO: HELENA SALES, POC SPECALISTS, INTERNATIONAL DISTRIBUTORS FROM: HELENA HEMOSTASIS/POINT OF CARE SUBJECT: ROUND-UP DATE: 11/10/2010 General News It has been a while since the last issue but every time

More information

The Swedish Drug Development Pipeline June 2012. A survey conducted by:

The Swedish Drug Development Pipeline June 2012. A survey conducted by: The Swedish Drug Development Pipeline June 2012 A survey conducted by: Key findings More companies report clinical trials There has been a increase in number of companies contributing with information

More information

Global Non-Small Cell Lung Cancer Therapeutics Market 2015-2019

Global Non-Small Cell Lung Cancer Therapeutics Market 2015-2019 Brochure More information from http://www.researchandmarkets.com/reports/3453273/ Global Non-Small Cell Lung Cancer Therapeutics Market 2015-2019 Description: About non-small cell lung cancer therapeutics

More information

6 th Proactive GCP Compliance Effective Risk- Based Approaches for Optimizing Clinical Quality

6 th Proactive GCP Compliance Effective Risk- Based Approaches for Optimizing Clinical Quality 6 th Proactive GCP Compliance Effective Risk- Based Approaches for Optimizing Clinical Quality March 24-25, 2015 Wyndham Philadelphia Historic District, Philadelphia, PA www.exlevents.com/gcp Sponsors

More information

A PATIENT S GUIDE TO DEEP VEIN THROMBOSIS TREATMENT

A PATIENT S GUIDE TO DEEP VEIN THROMBOSIS TREATMENT A PATIENT S GUIDE TO DEEP VEIN THROMBOSIS TREATMENT This medicine is subject to additional monitoring. This will allow quick identification of new safety information. If you get any side effects, talk

More information

TABLE OF COMMITMENTS

TABLE OF COMMITMENTS Reaching Goals On, a range of public and private partners are announcing a new, coordinated push to accelerate progress toward eliminating or controlling 10 neglected tropical diseases (NTDs) by in support

More information

LOW T NATION TESTOSTERONE INTAKE FORM NAME: DATE: ADDRESS: CITY: STATE: ZIP: CELL #: HOME #: SOC SECURITY #: DATE OF BIRTH:

LOW T NATION TESTOSTERONE INTAKE FORM NAME: DATE: ADDRESS: CITY: STATE: ZIP: CELL #: HOME #: SOC SECURITY #: DATE OF BIRTH: LOW T NATION TESTOSTERONE INTAKE FORM NAME: DATE: ADDRESS: CITY: STATE: ZIP: CELL #: HOME #: SOC SECURITY #: DATE OF BIRTH: DRIVERS LICENSE NUMBER: STATE: EMAIL ADDRESS: MARITAL STATUS: ( ) SINGLE ( )

More information

Analyzing the Global Diabetes Market 2016

Analyzing the Global Diabetes Market 2016 Brochure More information from http://www.researchandmarkets.com/reports/2060216/ Analyzing the Global Diabetes Market 2016 Description: Diabetes is a chronic disease in which there are high levels of

More information

Certificate of Equivalence of Core Surgical Training

Certificate of Equivalence of Core Surgical Training Certificate of Equivalence of Core Surgical Training This certificate may be required to confirm the competences expected at completion of core surgical training. ALL other applicants should have this

More information

Introduction to Insulin. Your guide to taking insulin

Introduction to Insulin. Your guide to taking insulin Introduction to Insulin Your guide to taking insulin Introduction Insulin helps control the level of blood glucose in the body. Everyone with type 1 diabetes must take insulin, and many people with type

More information

sexual after Being prostate cancer... Manitoba Prostate Centre Visit our website at www.cancercare.mb.ca

sexual after Being prostate cancer... Manitoba Prostate Centre Visit our website at www.cancercare.mb.ca Manitoba Prostate Centre Being sexual after prostate cancer... Visit our website at www.cancercare.mb.ca This publication is supported by an unrestricted educational grant from Pfizer Canada Inc. Treatment

More information

Global Peptide Therapeutics Market 2014-2018

Global Peptide Therapeutics Market 2014-2018 Brochure More information from http://www.researchandmarkets.com/reports/3022209/ Global Peptide Therapeutics Market 2014-2018 Description: About Peptide Therapeutics Peptides are amino acids sequences

More information

PROGRAM PLAN FOR THE ONTARIO MEDICATIONS RETURN PROGRAM

PROGRAM PLAN FOR THE ONTARIO MEDICATIONS RETURN PROGRAM PROGRAM PLAN FOR THE ONTARIO MEDICATIONS RETURN PROGRAM April 2013 Executive Summary Ontario Regulation 298/12 "Collection of Pharmaceuticals and Sharps - Responsibility of Producers" came into force on

More information

CODE FOR DISCLOSURE OF TRANSFERS OF VALUE BY PHARMACEUTICAL COMPANIES TO HEALTHCARE PROFESSIONALS AND HEALTH ORGANIZATIONS

CODE FOR DISCLOSURE OF TRANSFERS OF VALUE BY PHARMACEUTICAL COMPANIES TO HEALTHCARE PROFESSIONALS AND HEALTH ORGANIZATIONS CODE FOR DISCLOSURE OF TRANSFERS OF VALUE BY PHARMACEUTICAL COMPANIES TO HEALTHCARE PROFESSIONALS AND HEALTH ORGANIZATIONS Adopted November 2013, in force since 1 st of January 2014. INTRODUCTION The Association

More information

The largest clinical study of Bayer's Xarelto (rivaroxaban) Wednesday, 14 November 2012 07:38

The largest clinical study of Bayer's Xarelto (rivaroxaban) Wednesday, 14 November 2012 07:38 Bayer HealthCare has announced the initiation of the COMPASS study, the largest clinical study of its oral anticoagulant Xarelto (rivaroxaban) to date, investigating the prevention of major adverse cardiac

More information

PULMONARY ARTERIAL HYPERTENSION AGENTS

PULMONARY ARTERIAL HYPERTENSION AGENTS Approvable Criteria: PULMONARY ARTERIAL HYPERTENSION AGENTS Brand Name Generic Name Length of Authorization Revatio Sildenafil citrate Calendar Year Adcirca Tadalafil Calendar Year Letairis Ambrisentan

More information

Scott Byrne & Rachel Weeks G400: Pharma Report 10/22/09 Direct to Consumer Advertising: The Affect on the Pharmaceutical Industry

Scott Byrne & Rachel Weeks G400: Pharma Report 10/22/09 Direct to Consumer Advertising: The Affect on the Pharmaceutical Industry Scott Byrne & Rachel Weeks G400: Pharma Report 10/22/09 Direct to Consumer Advertising: The Affect on the Pharmaceutical Industry A Glance at the Pharmaceutical Industry The pharmaceutical industry is

More information

February 2016. page 1 / 9

February 2016. page 1 / 9 February 2016 page 1 / 9 page 2 / 9 Alternative Medicines Corner Advising on this article: Nicole M. Maisch February 1, 2016 Melatonin supplementation may improve outcomes in children with atopic dermatitis

More information

Kevin Saunders MD CCFP Rivergrove Medical Clinic Wellness Institute @ SOGH April 17 2013

Kevin Saunders MD CCFP Rivergrove Medical Clinic Wellness Institute @ SOGH April 17 2013 Kevin Saunders MD CCFP Rivergrove Medical Clinic Wellness Institute @ SOGH April 17 2013 Family physician with Rivergrove Medical Clinic Practice in the north end since 1985 Medical Director of the Wellness

More information

Outsourcing and Offshoring of R&D in the Pharmaceutical Industry: Evidence and Policy Implications from a Global Value Chain Analysis

Outsourcing and Offshoring of R&D in the Pharmaceutical Industry: Evidence and Policy Implications from a Global Value Chain Analysis Outsourcing and Offshoring of R&D in the Pharmaceutical Industry: Evidence and Policy Implications from a Global Value Chain Analysis Paulina Ramirez: Birmingham Business School IRIMA Workshop on the Internationalisation

More information

Are insulin analogs worth their cost in type 2 diabetes?

Are insulin analogs worth their cost in type 2 diabetes? Keystone, Colorado 2012 Are insulin analogs worth their cost in type 2 diabetes? Dr. Amanda Adler Consultant Physician, Institute of Metabolic Sciences Addenbrooke s Hospital, Cambridge Chair, Technology

More information

Integrated Approach to Build Patient Adherence: Helping Pharmaceutical Companies to Enhance Growth

Integrated Approach to Build Patient Adherence: Helping Pharmaceutical Companies to Enhance Growth Cognizant White Paper Integrated Approach to Build Patient Adherence: Helping Pharmaceutical Companies to Enhance Growth Executive Summary Pharmaceutical companies have traditionally considered various

More information

Shared Care Agreement Insulin Degludec (Tresiba )

Shared Care Agreement Insulin Degludec (Tresiba ) Licensed Indication Shared Care Agreement Insulin Degludec (Tresiba ) Insulin Degludec is licensed for the treatment of diabetes mellitus in adults. Countess of Chester prescribing guidelines Restricting

More information

Company Presentation June 2011 Biotest AG 0

Company Presentation June 2011 Biotest AG 0 Company Presentation June 2011 0 Disclaimer This document contains forward-looking statements on overall economic development as well as on the business, earnings, financial and asset situation of and

More information

Portfolio of Offerings

Portfolio of Offerings Portfolio of Offerings Byram Healthcare s One Source Total Solution provides extensive service and support to all those living with diabetes! We are a full service diabetes care provider offering all brand

More information

Pipeline Insight: Schizophrenia Asenapine; A future market leader?

Pipeline Insight: Schizophrenia Asenapine; A future market leader? A Datamonitor report Pipeline Insight: Schizophrenia Asenapine; A future market leader? Published: Jul-06 Product Code: DMHC2186 Providing you with: Detailed pipeline analysis for key products in development

More information

East Kent Prescribing Group

East Kent Prescribing Group East Kent Prescribing Group Rivaroxaban (Xarelto ) Safety Information Approved by the East Kent Prescribing Group. Approved by: East Kent Prescribing Group (Representing Ashford CCG, Canterbury and Coastal

More information

Summary of the risk management plan (RMP) for Xultophy (insulin degludec / liraglutide)

Summary of the risk management plan (RMP) for Xultophy (insulin degludec / liraglutide) EMA/467911/2014 Summary of the risk management plan (RMP) for Xultophy (insulin degludec / liraglutide) This is a summary of the risk management plan (RMP) for Xultophy, which details the measures to be

More information

Investor News. Not intended for U.S. and UK media

Investor News. Not intended for U.S. and UK media Investor News Not intended for U.S. and UK media Bayer AG Investor Relations 51368 Leverkusen Germany www.investor.bayer.com Bayer s Xarelto (Rivaroxaban) Approved for the Treatment of Pulmonary Embolism

More information

Pharmacovigilance Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013-2019 Single User License: US $ 4595

Pharmacovigilance Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013-2019 Single User License: US $ 4595 Transparency Market Research Pharmacovigilance Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013-2019 Single User License: US $ 4595 Buy Now Request Sample Published Date:

More information

BOLT Hem/Onc Thought Leader Panel #38 Cancer Immunotherapy 2014-05

BOLT Hem/Onc Thought Leader Panel #38 Cancer Immunotherapy 2014-05 Syndicated Thought Leader Insight Healthcare & Pharmaceutical Research Cancer Immunotherapy Melanoma, Non- Small Cell Lung Cancer, Renal Cell Carcinoma Thought Leader Panel #38 2014-05 Therapeutic Area:

More information

The Cell Therapy Catapult

The Cell Therapy Catapult The Cell Therapy Catapult Keith Thompson CEO January 29 2013 [email protected] Catapult is a Technology Strategy Board programme The Launch of Catapults Hauser 2 Hauser Report Creating new manufacturing

More information

In the largest and perhaps the most ambitious collaborative

In the largest and perhaps the most ambitious collaborative FEATURES THE BIRTH OF TRANSCELERATE BIOPHARMA, INC. Revolution in Clinical Research Partnerships by Dalvir Gill and Garry Neil In the largest and perhaps the most ambitious collaborative effort ever initiated

More information

Pharmaceutical industry

Pharmaceutical industry 8 th March 2016 Pharmaceutical industry 2015 Global ranking strategy decisive The annual company reporting season is always an exciting period. It is an ideal time to update our industry statistics and

More information

Traveller s Thrombosis. Dr. Peter Verhamme Vascular Medicine and Haemostasis UZ Leuven

Traveller s Thrombosis. Dr. Peter Verhamme Vascular Medicine and Haemostasis UZ Leuven Traveller s Thrombosis Dr. Peter Verhamme Vascular Medicine and Haemostasis UZ Leuven Case 1: To thromboprophylaxe or not Women, aged 49, BMI 29, Combined Oral Contraceptives. Family history of provoked

More information

from PKI to Identity Assurance

from PKI to Identity Assurance from PKI to Identity Assurance Richard Trevorah Technical Manager tscheme Ltd Tel: +44 (0)7818 094728 [email protected] What is tscheme? tscheme is a not-for-profit membership organisation chartered

More information

Catheter Embolization and YOU

Catheter Embolization and YOU Catheter Embolization and YOU What is catheter embolization? Embolization therapy is a minimally invasive (non-surgical) treatment that occludes or blocks one or more blood vessels or vascular channels

More information

How To Get A Dose Of Bayer Healthcare'S Oral Anticoagulant, Xarelto

How To Get A Dose Of Bayer Healthcare'S Oral Anticoagulant, Xarelto News Release FOR UK HEALTHCARE MEDIA ONLY Bayer HealthCare Bayer plc Bayer House Strawberry Hill Newbury Berkshire, RG14 1JA www.bayer.co.uk Bayer s Xarelto (rivaroxaban) Recommended by CHMP for EU Approval

More information

Clinical trial research agreement Agreed schedule 4 or 7 clause amendments

Clinical trial research agreement Agreed schedule 4 or 7 clause amendments Clinical trial research agreement Agreed schedule 4 or 7 clause amendments Medicines Australia and Medical Technology Association of Australia templates The sponsors in the table have agreed clauses for

More information